PL358456A1 - Bimer lub oligomer dimerów, trimerów, kwadoromerów lub pentamerów rekombinowanych białek fuzyjnych - Google Patents

Bimer lub oligomer dimerów, trimerów, kwadoromerów lub pentamerów rekombinowanych białek fuzyjnych

Info

Publication number: PL358456A1
Authority: PL; Poland
Prior art keywords: fragment; protein; fusion proteins; recombinant fusion; collectin
Prior art date: 1999-12-30

Application number

PL00358456A

Other languages

English (en)

Other versions

PL204277B1 (pl

Inventor

Jurg Tschopp

Pascal Schneider

Nils Holler

Original Assignee

Apoxis Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-30

Filing date

2000-12-20

Publication date

2004-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7935052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL358456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-20 Application filed by Apoxis Sa filed Critical Apoxis Sa

2004-08-09 Publication of PL358456A1 publication Critical patent/PL358456A1/pl

2009-12-31 Publication of PL204277B1 publication Critical patent/PL204277B1/pl

Links

102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 3
239000000539 dimer Substances 0.000 title abstract 3
239000013638 trimer Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 6
108090000623 proteins and genes Proteins 0.000 abstract 6
239000012634 fragment Substances 0.000 abstract 5
102000037865 fusion proteins Human genes 0.000 abstract 5
108020001507 fusion proteins Proteins 0.000 abstract 5
102000004405 Collectins Human genes 0.000 abstract 2
108090000909 Collectins Proteins 0.000 abstract 2
238000006471 dimerization reaction Methods 0.000 abstract 2
238000006384 oligomerization reaction Methods 0.000 abstract 2
108060003951 Immunoglobulin Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000002424 anti-apoptotic effect Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000000078 anti-malarial effect Effects 0.000 abstract 1
230000000842 anti-protozoal effect Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
230000000840 anti-viral effect Effects 0.000 abstract 1
239000003430 antimalarial agent Substances 0.000 abstract 1
239000003904 antiprotozoal agent Substances 0.000 abstract 1
230000001640 apoptogenic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002124 endocrine Effects 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
230000002519 immonomodulatory effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
102000018358 immunoglobulin Human genes 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
230000011664 signaling Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Plant Pathology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)

PL358456A 1999-12-30 2000-12-20 Białko fuzyjne, jego bi-lub oligomer, ich zastosowania, sekwencja DNA, wektor ekspresyjny, komórka gospodarza oraz środek farmaceutyczny PL204277B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19963859A DE19963859A1 (de)	1999-12-30	1999-12-30	Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
PCT/EP2000/013032 WO2001049866A1 (de)	1999-12-30	2000-12-20	Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen

Publications (2)

Publication Number	Publication Date
PL358456A1 true PL358456A1 (pl)	2004-08-09
PL204277B1 PL204277B1 (pl)	2009-12-31

Family

ID=7935052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL358456A PL204277B1 (pl)	1999-12-30	2000-12-20	Białko fuzyjne, jego bi-lub oligomer, ich zastosowania, sekwencja DNA, wektor ekspresyjny, komórka gospodarza oraz środek farmaceutyczny

Country Status (19)

Country	Link
US (6)	US7385032B2 (pl)
EP (2)	EP1246925B1 (pl)
JP (1)	JP5031165B2 (pl)
KR (1)	KR100767980B1 (pl)
CN (1)	CN100385002C (pl)
AT (1)	ATE397076T1 (pl)
AU (1)	AU783833B2 (pl)
BR (1)	BRPI0017054B1 (pl)
CA (1)	CA2395632C (pl)
CY (1)	CY1108195T1 (pl)
DE (2)	DE19963859A1 (pl)
DK (1)	DK1246925T3 (pl)
ES (1)	ES2307550T3 (pl)
HU (1)	HU229204B1 (pl)
IL (2)	IL150215A0 (pl)
PL (1)	PL204277B1 (pl)
PT (1)	PT1246925E (pl)
WO (1)	WO2001049866A1 (pl)
ZA (1)	ZA200205069B (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7300774B1 (en)	1999-12-09	2007-11-27	The Regents Of The University Of California	Multimeric fusion proteins of the TNF superfamily ligands
US20030095967A1 (en) *	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) *	2001-07-24	2005-05-12	Biogen Idec Ma Inc.	BAFF, inhibitors thereof and their use in the modulation of B-cell response
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE19963859A1 (de) *	1999-12-30	2001-07-12	Apotech Res & Dev Ltd	Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2410525A1 (en) *	2000-05-26	2001-11-29	Mochida Pharmaceuticals Co., Ltd.	Fas ligand-fused proteins
GB0015426D0 (en) *	2000-06-24	2000-08-16	Univ Southampton	Method for generating soluble highly multimeric proteins
CA2435000C (en) *	2001-01-18	2014-03-25	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
DE10122140A1 (de) *	2001-05-08	2002-11-28	Apotech Res & Dev Ltd	Rekombinante Fusionsproteine und deren Trimere
CN100335900C (zh) *	2001-11-30	2007-09-05	加拿大国家研究局	新的自组装分子
WO2003068977A2 (de) *	2002-02-10	2003-08-21	Apoxis Sa	Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US20080267965A1 (en) *	2002-02-21	2008-10-30	Kalled Susan L	Use of Bcma as an Immunoregulatory Agent
WO2003095489A1 (en) *	2002-05-08	2003-11-20	Apoxis S.A.	Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the same
FR2840307B1 (fr) *	2002-05-30	2006-07-07	Centre Nat Rech Scient	Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
DE10247755B4 (de) *	2002-10-14	2006-01-19	Pfizenmaier, Klaus, Prof. Dr.	Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
US20070010658A1 (en) *	2002-10-29	2007-01-11	Holtet Thor L	Trimeric binding proteins for trimeric cytokines
PT1606318E (pt)	2003-03-26	2009-11-10	Deutsches Krebsforsch	Proteínas de fusão de fc melhoradas
PL2298347T3 (pl) *	2003-05-06	2016-03-31	Bioverativ Therapeutics Inc	Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) *	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
EP1481686A1 (en) *	2003-05-26	2004-12-01	Apoxis SA	Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases
US20050143297A1 (en) *	2003-05-26	2005-06-30	Jean-Pierre Rosat	Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
DE102004014983A1 (de) *	2004-03-26	2005-10-20	Univ Stuttgart	Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
AU2005291298B2 (en) *	2004-10-01	2012-01-19	Apoxis Sa	Method for ex-vivo purging in autologous transplantation
FR2879202B1 (fr) *	2004-12-15	2007-02-23	Centre Nat Rech Scient Cnrse	Nouveaux ligands multimeriques de cd40, leur procede de preparation et leur utilisation pour la preparation de medicaments
WO2006077232A2 (en) *	2005-01-20	2006-07-27	Apoxis Sa	Multimeric soluble fas ligand for eliminating alloreactive t lymphocyte in allogenic harmatopoietic stem-cell transplantation transplantation
AU2006284922B2 (en)	2005-08-30	2012-01-19	University Of Miami	Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
EP2441846A3 (en) *	2006-01-09	2012-07-25	The Regents Of the University of California	Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
WO2007117339A2 (en) *	2006-01-11	2007-10-18	The United States Of America As Respresented By The Secretary Of The Navy	Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
ES2560871T3 (es) *	2007-07-10	2016-02-23	Apogenix Gmbh	Proteínas de fusión de colectina de la superfamilia de TNF
ES2538122T3 (es)	2008-07-21	2015-06-17	Apogenix Gmbh	Moléculas de una sola cadena de TNFSF
WO2010051502A2 (en) *	2008-10-31	2010-05-06	Biogen Idec Ma Inc.	Light targeting molecules and uses thereof
US8664366B2 (en)	2009-01-09	2014-03-04	Apogenix Gmbh	Fusion proteins forming trimers
WO2010102518A1 (zh) *	2009-03-13	2010-09-16	北京表源生物技术有限公司	一种融合蛋白多聚体
US8486421B2 (en)	2009-06-09	2013-07-16	Children's Hospital Medical Center	Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use
SG10201502330TA (en)	2009-08-03	2015-05-28	Univ Miami	Method for in vivo expansion of t regulatory cells
US10822396B2 (en)	2009-12-15	2020-11-03	MuHyeon CHOE	Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
EP2518078B1 (en) *	2009-12-15	2020-05-20	Choe, Muhyeon	Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
WO2012040101A1 (en)	2010-09-21	2012-03-29	University Of Miami	Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) *	2010-09-24	2012-03-29	University Of Miami	Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
AU2012222833B2 (en) *	2011-03-03	2017-03-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
AU2013219968B2 (en) *	2012-02-15	2018-11-08	Biocon Limited	A process for detection and optional quantification of an analyte
US9562077B2 (en)	2012-07-11	2017-02-07	Children's Hospital Medical Center	Protein complex system for increased immunogenicity and functionality, and methods making and use
WO2014012082A2 (en)	2012-07-13	2014-01-16	Zymeworks Inc.	Multivalent heteromultimer scaffold design an constructs
US20140193410A1 (en)	2013-01-09	2014-07-10	University Of Miami	Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
AU2014233114B2 (en)	2013-03-15	2018-03-08	Richard S. Kornbluth	Composition comprised of antigen linked to a TNF SuperFamily ligand
WO2014144549A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Factor ix polypeptide formulations
WO2014179494A1 (en) *	2013-04-30	2014-11-06	Colorado State University Research Foundation	Sensors and assays for ubiquitin or ubiquitin-like proteins
CN105683754B (zh) *	2013-05-30	2019-02-01	崔武铉	由重复链和单体的复合物交叉形成的超级复合物及其应用
US9321803B2 (en)	2013-07-12	2016-04-26	Children's Hospital Medical Center	Compositions and methods for inhibiting norovirus infection
CN104299540A (zh) *	2013-07-15	2015-01-21	驰众信息技术（上海）有限公司	广告互动播放系统及其广告机终端
NO2776305T3 (pl)	2014-04-23	2018-01-27
JP2014218510A (ja) *	2014-08-11	2014-11-20	アポゲニクスゲゼルシャフトミットベシュレンクテルハフツングＡｐｏｇｅｎｉｘＧｍｂＨ	三量体形成融合タンパク質
CN104356233B (zh) *	2014-10-11	2017-09-29	中国科学院微生物研究所	一种人热休克蛋白gp96的scFv抗体及其制备方法与应用
WO2016112983A1 (en)	2015-01-15	2016-07-21	Biontech Ag	Cytokine fusion proteins
IL308212A (en)	2015-01-20	2024-01-01	Igm Biosciences Inc	Tumor necrosis factor-α receptor binding molecules and their uses
MA41460A (fr)	2015-02-03	2017-12-12	Oncomed Pharm Inc	Agents de liaison à la tnfrsf et leurs utilisations
ES2754432T3 (es)	2015-05-04	2020-04-17	Apogenix Ag	Proteínas agonistas de receptor CD40 de cadena sencilla
JP2018522571A (ja) *	2015-08-12	2018-08-16	メディミューンリミテッド	Ｇｉｔｒｌ融合タンパク質およびその使用
EP3364995B1 (en)	2015-10-23	2021-08-04	Apogenix AG	Single-chain cd27-receptor agonist proteins
CA3002741A1 (en)	2015-10-23	2017-04-27	Apogenix Ag	Single-chain gitr-receptor agonist proteins
CA3002587A1 (en)	2015-10-23	2017-04-27	Apogenix Ag	Single-chain light receptor agonist proteins
WO2017072080A1 (en)	2015-10-28	2017-05-04	Apogenix Ag	Single-chain tl1a receptor agonist proteins
EP3231813A1 (en)	2016-03-29	2017-10-18	F. Hoffmann-La Roche AG	Trimeric costimulatory tnf family ligand-containing antigen binding molecules
AU2017245143B2 (en)	2016-03-30	2024-01-11	Ab Biosciences, Inc.	Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
AU2016419048B2 (en)	2016-08-11	2024-02-15	The Council Of The Queensland Institute Of Medical Research	Immune-modulating compounds
WO2018115305A1 (en) *	2016-12-22	2018-06-28	Leibniz-Institut für Pflanzengenetik Und Kulturpflanzenforschung (IPK)	Oligomeric vaccines from plants by s-tag-s-protein fusions
EP3600397A4 (en)	2017-03-28	2021-01-27	Children's Hospital Medical Center	NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
WO2018178074A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3678699A1 (en)	2017-09-07	2020-07-15	University Of Oslo	Vaccine molecules
CN112552415B (zh) *	2021-02-22	2021-06-22	北京百普赛斯生物科技股份有限公司	B淋巴细胞刺激因子十二聚体及其制备方法与应用
CA3219201A1 (en) *	2021-05-06	2022-11-10	Hipra Scientific, S.L.U.	Sars-cov-2 subunit vaccine
KR20240013766A (ko) *	2021-05-27	2024-01-30	베이징 안신화이더 바이오텍. 씨오., 엘티디	2개의 trail 삼량체를 포함하는 수퍼-trail 분자
AU2023300419A1 (en)	2022-07-01	2025-01-02	Transgene	Fusion protein comprising a surfactant-protein-d and a member of the tnfsf

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5859330A (en) *	1989-12-12	1999-01-12	Epitope, Inc.	Regulated expression of heterologous genes in plants and transgenic fruit with a modified ripening phenotype
US5763733A (en) *	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US5869330A (en) *	1995-06-05	1999-02-09	Whitehead Institute For Biomedical Research	DNA encoding a novel serum protein produced exclusively in adipocytes
WO1997033617A1 (en) *	1996-03-13	1997-09-18	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
US6165476A (en) *	1997-07-10	2000-12-26	Beth Israel Deaconess Medical Center	Fusion proteins with an immunoglobulin hinge region linker
HUP0003762A3 (en) *	1997-07-18	2005-11-28	Zymogenetics Inc	Adipocyte-specific protein homologs
JP4057127B2 (ja) *	1998-02-19	2008-03-05	セイコーエプソン株式会社	アクティブマトリックス基板及びアクティブマトリックス基板の製造方法並びに液晶装置
JP2002504342A (ja) *	1998-02-19	2002-02-12	プレジデントアンドフェローズオブハーバードカレッジ	一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
US7300774B1 (en) *	1999-12-09	2007-11-27	The Regents Of The University Of California	Multimeric fusion proteins of the TNF superfamily ligands
JP2003501027A (ja) *	1999-05-27	2003-01-14	ザイモジェネティクス，インコーポレイティド	脂肪細胞補体関連タンパク質同族体ｚａｃｒｐ５
MXPA02001417A (es) *	1999-08-09	2002-08-12	Lexigen Pharm Corp	Complejos multiples de citosina-anticuerpo.
DE19963859A1 (de) *	1999-12-30	2001-07-12	Apotech Res & Dev Ltd	Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen

1999
- 1999-12-30 DE DE19963859A patent/DE19963859A1/de not_active Withdrawn
2000
- 2000-12-20 WO PCT/EP2000/013032 patent/WO2001049866A1/de not_active Ceased
- 2000-12-20 AU AU23673/01A patent/AU783833B2/en not_active Ceased
- 2000-12-20 KR KR1020027008522A patent/KR100767980B1/ko not_active Expired - Fee Related
- 2000-12-20 EP EP00987425A patent/EP1246925B1/de not_active Expired - Lifetime
- 2000-12-20 PL PL358456A patent/PL204277B1/pl unknown
- 2000-12-20 HU HU0203628A patent/HU229204B1/hu not_active IP Right Cessation
- 2000-12-20 DK DK00987425T patent/DK1246925T3/da active
- 2000-12-20 JP JP2001550394A patent/JP5031165B2/ja not_active Expired - Fee Related
- 2000-12-20 EP EP08103225A patent/EP1985706A3/de not_active Withdrawn
- 2000-12-20 CN CNB008181004A patent/CN100385002C/zh not_active Expired - Fee Related
- 2000-12-20 AT AT00987425T patent/ATE397076T1/de active
- 2000-12-20 IL IL15021500A patent/IL150215A0/xx active IP Right Grant
- 2000-12-20 ES ES00987425T patent/ES2307550T3/es not_active Expired - Lifetime
- 2000-12-20 PT PT00987425T patent/PT1246925E/pt unknown
- 2000-12-20 BR BRPI0017054A patent/BRPI0017054B1/pt not_active IP Right Cessation
- 2000-12-20 DE DE50015185T patent/DE50015185D1/de not_active Expired - Lifetime
- 2000-12-20 CA CA2395632A patent/CA2395632C/en not_active Expired - Lifetime
2002
- 2002-06-13 IL IL150215A patent/IL150215A/en unknown
- 2002-06-24 ZA ZA200205069A patent/ZA200205069B/xx unknown
- 2002-06-28 US US10/185,425 patent/US7385032B2/en not_active Expired - Lifetime
2004
- 2004-06-18 US US10/871,776 patent/US20040235117A1/en not_active Abandoned
2008
- 2008-06-02 US US12/131,478 patent/US20090053252A1/en not_active Abandoned
- 2008-07-14 CY CY20081100738T patent/CY1108195T1/el unknown
2011
- 2011-03-31 US US13/077,512 patent/US20120009211A1/en not_active Abandoned
2013
- 2013-02-11 US US13/764,322 patent/US20130202552A1/en not_active Abandoned
2014
- 2014-04-29 US US14/264,402 patent/US20150004129A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CY1108195T1 (el)	2014-02-12
US20030053984A1 (en)	2003-03-20
WO2001049866A1 (de)	2001-07-12
DE50015185D1 (de)	2008-07-10
US20130202552A1 (en)	2013-08-08
IL150215A (en)	2008-11-26
CA2395632C (en)	2012-08-28
PL204277B1 (pl)	2009-12-31
AU783833B2 (en)	2005-12-08
EP1246925A1 (de)	2002-10-09
JP2003518949A (ja)	2003-06-17
US20120009211A1 (en)	2012-01-12
US7385032B2 (en)	2008-06-10
ATE397076T1 (de)	2008-06-15
HUP0203628A2 (en)	2003-02-28
CN1526020A (zh)	2004-09-01
ES2307550T3 (es)	2008-12-01
DE19963859A1 (de)	2001-07-12
US20090053252A1 (en)	2009-02-26
KR20020089319A (ko)	2002-11-29
US20040235117A1 (en)	2004-11-25
IL150215A0 (en)	2002-12-01
DK1246925T3 (da)	2008-09-01
CN100385002C (zh)	2008-04-30
BR0017054A (pt)	2003-01-07
BRPI0017054B1 (pt)	2017-04-04
AU2367301A (en)	2001-07-16
US20150004129A1 (en)	2015-01-01
HU229204B1 (hu)	2013-09-30
PT1246925E (pt)	2008-08-11
EP1985706A2 (de)	2008-10-29
KR100767980B1 (ko)	2007-10-18
ZA200205069B (en)	2004-03-24
JP5031165B2 (ja)	2012-09-19
EP1985706A3 (de)	2009-05-13
EP1246925B1 (de)	2008-05-28
CA2395632A1 (en)	2001-07-12

Publication	Publication Date	Title
ZA200205069B (en)	2004-03-24	Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins.
Waterfield et al.	1983	Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
Koppel et al.	1998	Collapsin-1 covalently dimerizes, and dimerization is necessary for collapsing activity
DE69831754D1 (de)	2006-02-09	Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
NO20000934L (no)	2000-04-26	Adipocyttspesifikke proteinhomologer
GB1285299A (en)	1972-08-16	Ethylene oligomerization in the presence of nickel- and fluorine-containing catalysts
DE69533255D1 (de)	2004-08-19	ISOLIERTES p27 PROTEIN UND NUKLEINSÄURE DAFÜR KODIEREND
WO1997033995A3 (en)	1998-01-08	Extracellular matrix signalling molecules
MY119209A (en)	2005-04-30	Process for oligomerizing olefins
DK0970213T3 (da)	2007-05-21	Dödsdomæneholdig receptor
DE69129803D1 (de)	1998-08-20	Wasserlösliche peptidanaloguen mit bindungstellen
ATE243253T1 (de)	2003-07-15	Rezeptoren der wachstumsfaktoren aus fibroblasten
ATE394492T1 (de)	2008-05-15	Verfahren zur oligomerisation von peptiden
DE69834643D1 (de)	2006-06-29	Adipozyten-spezifische protein homologe
ATE335818T1 (de)	2006-09-15	Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung
DK0689599T3 (da)	1999-08-16	Kimære selectiner ved udveksling af domæner og anvendelser deraf
Krautwald et al.	1993	Bacterially expressed murine CSF-1 possesses agonistic activity in its monomeric form
Pennington et al.	1990	Synthesis and biological activity of six monosubstituted analogs of a sea anemone polypeptide neurotoxin.
Spisani et al.	1992	New chemotactic peptide analogs with high biological activity for human neutrophils.
Englebretsen et al.	1994	High yield, directed immobilization of a peptide-ligand onto a beaded cellulose support.
FI925931A0 (fi)	1992-12-30	Menetelmä C4-olefiinien oligomeroimiseksi yhdessä lineaaristen alfa-olefiinien kanssa
Marikar et al.	1992	Characterization of concanavalin A-binding neuronal and glial surface glycoproteins from human foetal brain.
Alexenko et al.	1991	Mapping of an epitope of human leukocyte alpha interferon A which is recognized by the murine monoclonal antibody NK2.
WO2001000664A3 (en)	2001-05-03	Secreted alpha-helical protein-36
Fountoulakis	1996	Apparent heterogeneity of recombinant interferon γ receptors produced in prokaryotic and eukaryotic expression systems